News Headlines
-
Resilience And Jobsohio Announce Continued Partnership And Expansion In Blue Ash
3/26/2025
National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, announced today the next phase of its growth in the Cincinnati region.
-
AGC Biologics Honored For Excellence In Development And Manufacturing
3/25/2025
AGC Biologics won two 2025 CDMO Leadership Awards in the “Biologics – Global” and “Cell & Gene – Global” categories, based on independent industry surveys. The recognition highlights the company’s strength in innovation, manufacturing, and quality, and its commitment to supporting biopharma companies worldwide.
-
Singota Solutions Expands European Footprint To 3 Sites, Adds New State-Of-The-Art Facility In Balerna, Switzerland
3/25/2025
Singota Solutions, a trusted partner for pharmaceutical development and cGMP sterile drug product manufacturing as well as supply chain services, announces the opening of its new facility in Balerna, Switzerland.
-
Benuvia Operations Awarded NIH Contract For GMP Synthesis Of Psilocybin And Other Bulk Drug Substances
3/25/2025
Benuvia Operations, LLC (Benuvia), a global contract development and manufacturing organization, today announced that it has been awarded a five-year contract by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), for the Good Manufacturing Practice (GMP) synthesis of psilocybin and other bulk drug substances.
-
Merck Enters Exclusive License Agreement For HRS-5346, An Investigational Oral Lipoprotein(a) Inhibitor, For Cardiovascular Disease From Jiangsu Hengrui Pharmaceuticals Co., Ltd.
3/25/2025
Merck, known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, today announced that the companies have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China.
-
Cytiva Broadens Xcellerex X-Platform To include 500L And 2 000L Bioreactors
3/25/2025
As researchers and scientists work to discover the next generation of advanced therapeutics, Cytiva is expanding the Xcellerex X-platform portfolio to meet their growing needs with the addition of 500L and 2 000L bioreactors.
-
Verista Highlights COUNTQ Tray Inspection Systems
3/25/2025
Verista, a leading provider of automation, compliance, and quality solutions for the pharmaceutical industry, highlights the COUNTQ Tray Inspection System, an advanced AI-enabled inspection and reconciliation system designed to revolutionize the counting and verification of vials, syringes, ampoules, and other tray-loaded parts in pharmaceutical manufacturing.
-
CARBOGEN AMCIS Secures GMP Certification After Successful ANSM Inspection For Its Aseptic Drug Product Manufacturing Site
3/24/2025
Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce the successful completion of the first inspection by the French regulatory authority, ANSM (Agence nationale de sécurité du médicament et des produits de santé), at its state-of-the-art sterile drug product manufacturing site in Saint-Beauzire, France.
- Upperton Pharma Solutions Wins Champion Award At 2025 CDMO Leadership Awards In Small Molecule Dosage Form Category 3/24/2025
-
Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For Ac-225 Radioisotope To Support Comprehensive Development Activities
3/24/2025
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler.